Elanco Animal Health Inc reported third quarter 2026 revenue of $1.265 billion, representing an 11% increase year-over-year, and net income of $18 million. Driven by strong demand and gross margin expansion, the company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted earnings per share.
Third quarter revenue reached $1.265 billion, up 11% reported and 9% organic constant currency.
Reported net income was $18 million, while adjusted EPS was $0.27.
Full year 2026 revenue guidance was raised to $5.155 billion to $5.18 billion.
Net leverage ratio improved to 2.9x Adjusted EBITDA at the end of the third quarter.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Elanco's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$4.71B
+6.2%
$-0.47
-169.1%
-4.9%
FY2024
$4.44B
+0.5%
$0.68
—
7.6%
FY2023
$4.42B
+0.1%
$-2.50
—
-27.9%
FY2022
$4.41B
-7.4%
$-0.16
—
-1.8%
FY2021
$4.76B
+45.6%
$-0.99
—
-10.1%
Frequently asked questions
When is Elanco's next earnings date?
Elanco (ELAN) is scheduled to report on Friday, November 06, 2026 before the market opens. Analysts expect EPS of $0.20.
What did Elanco earn last quarter?
For the quarter ended Sep 2026, Elanco reported diluted EPS of $0.04 on revenue of $1.26B (+11.3%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.